Arzeda

  • About Arzeda
  • Team
  • News
  • Careers
  • About Arzeda
  • Team
  • News
  • Careers

Our History

In 2008 and 2010, computational biologists Eric Althoff, David Baker, Daniela Grabs and Alexandre Zanghellini published seminal papers that revolutionized enzyme design and engineering in the elite journals Science and Nature. For the first time, it was possible to by-pass billions of years of natural evolution and use computers to design new building blocks for life, enabling the efficient and sustainable production of almost any molecule.

With the aim of implementing this pioneering work, the team of scientists laid the groundwork for Arzeda Corporation with preliminary operations at the University of Washington Center for Commercialization (now CoMotion).
​
Today, Arzeda has built the world’s premier protein and pathway design software. The technology is being implemented alongside the latest synthetic biology techniques to create new enzymes and chemical products that can compete on performance, cost and sustainability.
​
Arzeda is firmly committed to harnessing the power of synthetic biology to provide clever solutions for today’s most pressing global needs. Above all, we believe our aims are best achieved in a vibrant discovery environment that fosters creativity, integrity and a dedication to scientific rigor and perseverance.
Picture
Picture
Picture
Picture
Picture

We are grateful for the previous and current support for technology development provided by these forward-looking federal agencies:

By combining natural and designer proteins in cells, Arzeda can then reprogram fermentation hosts to produce virtually any chemical. Arzeda’s Scylax™ software automates pathway design. Leveraging highly annotated proprietary databases, Scylax™ enumerates and ranks all the possible enzymatic routes employing natural and designer enzymes from any specified molecule to a desired target molecule.

Arzeda’s computational protein and pathway design is poised to transform both biocatalysis and fermentation, including biocatalytic manufacturing of difficult-to-synthesize drug intermediates and the sustainable production of fine and specialty chemicals not made in nature. Arzeda’s biological design technologies unlock the value of synthetic systems biology, where complex cellular function can be designed computationally.

From proteins to cellular function: synthetic systems biology

​From technology to impact: scale-up

At Arzeda, we understand that having designer proteins and pathways working in vitro or in flasks is only part of the equation to bring industrially valuable products to market. We are dedicated to working with our industrial partners to not only design, but also scale our products. Thanks to a recent infusion of capital, we are taking aggressive steps to rapidly develop scalable solutions for industrial enzymes, fine and specialty chemicals and other verticals we address. We are also working closely with our commercialization partners and contract manufacturing to access scalable capabilities.

Management

Meet Our Team

Alexandre Zanghellini, PhD

Picture

Founder and CEO


Daniela Grabs, PhD

Picture

Co-founder and CSO


Eric Althoff, PhD

Picture

Co-founder and CBO


Copyright © 2020 Arzeda